Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R N Jones

Showing results (721-730 of 818) with videos related to

Pageof 82
Sort By:
Journal of Clinical Microbiology|May 2, 2000
Comparison of agar diffusion methodologies for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patientsJ L Burns, L Saiman, S Whittier, et al.
Diagnostic Microbiology and Infectious Disease|July 1, 1993
Epidemiologic typing of multiply drug-resistant Pseudomonas aeruginosa isolated from an outbreak in an intensive care unitH S Sader, A C Pignatari, I L Leme, et al.
Diagnostic Microbiology and Infectious Disease|April 1, 1986
In vitro activity of DJ-6783 (a keto carboxylic acid) compared with six other orally administered antimicrobial agentsR N Jones, L W Ayers, A L Barry, et al.
Journal of Clinical Microbiology|November 29, 2001
Standardization of broth microdilution and disk diffusion susceptibility tests for Actinobacillus pleuropneumoniae and Haemophilus somnus: quality control standards for ceftiofur, enrofloxacin, florfenicol, gentamicin, penicillin, tetracycline, tilmicosin, and trimethoprim-sulfamethoxazoleP F McDermott, A L Barry, R N Jones, et al.
Diagnostic Microbiology and Infectious Disease|March 24, 2000
A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremiaS M Bhavnani, J A Drake, A Forrest, et al.
The Annals of Thoracic Surgery|August 1, 1987
Early myocardial revascularization for postinfarction anginaR N Jones, R Pifarré, H J Sullivan, et al.
Diagnostic Microbiology and Infectious Disease|May 1, 1987
RO 23-6240 (AM-833), a new fluoroquinolone: in vitro antimicrobial activity and tentative disk diffusion interpretive criteriaP C Fuchs, R N Jones, A L Barry, et al.
Diagnostic Microbiology and Infectious Disease|May 1, 1987
Quality control limits for microdilution susceptibility tests with aztreonam, imipenem, ceftriaxone, ceftazidime, ceftizoxime, cefuroxime, and cefonicidA L Barry, T L Gavan, R N Jones, et al.
Diagnostic Microbiology and Infectious Disease|July 1, 1986
In vitro evaluation of cefixime (FK027, FR17027, CL284635): spectrum against recent clinical isolates, comparative antimicrobial activity, beta-lactamase stability, and preliminary susceptibility testing criteriaP C Fuchs, R N Jones, A L Barry, et al.
Diagnostic Microbiology and Infectious Disease|November 1, 1990
Interpretive criteria, quality control guidelines, and drug stability studies for susceptibility testing of cefotaxime, cefoxitin, ceftazidime, and cefuroxime against Neisseria gonorrhoeaeR N Jones, P C Fuchs, J A Washington, et al.
Pageof 82

Showing results (721-730 of 818) with videos related to

Sort By:
Pageof 82
Journal of Clinical Microbiology|May 2, 2000
Comparison of agar diffusion methodologies for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patientsJ L Burns, L Saiman, S Whittier, et al.
Diagnostic Microbiology and Infectious Disease|July 1, 1993
Epidemiologic typing of multiply drug-resistant Pseudomonas aeruginosa isolated from an outbreak in an intensive care unitH S Sader, A C Pignatari, I L Leme, et al.
Diagnostic Microbiology and Infectious Disease|April 1, 1986
In vitro activity of DJ-6783 (a keto carboxylic acid) compared with six other orally administered antimicrobial agentsR N Jones, L W Ayers, A L Barry, et al.
Journal of Clinical Microbiology|November 29, 2001
Standardization of broth microdilution and disk diffusion susceptibility tests for Actinobacillus pleuropneumoniae and Haemophilus somnus: quality control standards for ceftiofur, enrofloxacin, florfenicol, gentamicin, penicillin, tetracycline, tilmicosin, and trimethoprim-sulfamethoxazoleP F McDermott, A L Barry, R N Jones, et al.
Diagnostic Microbiology and Infectious Disease|March 24, 2000
A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremiaS M Bhavnani, J A Drake, A Forrest, et al.
The Annals of Thoracic Surgery|August 1, 1987
Early myocardial revascularization for postinfarction anginaR N Jones, R Pifarré, H J Sullivan, et al.
Diagnostic Microbiology and Infectious Disease|May 1, 1987
RO 23-6240 (AM-833), a new fluoroquinolone: in vitro antimicrobial activity and tentative disk diffusion interpretive criteriaP C Fuchs, R N Jones, A L Barry, et al.
Diagnostic Microbiology and Infectious Disease|May 1, 1987
Quality control limits for microdilution susceptibility tests with aztreonam, imipenem, ceftriaxone, ceftazidime, ceftizoxime, cefuroxime, and cefonicidA L Barry, T L Gavan, R N Jones, et al.
Diagnostic Microbiology and Infectious Disease|July 1, 1986
In vitro evaluation of cefixime (FK027, FR17027, CL284635): spectrum against recent clinical isolates, comparative antimicrobial activity, beta-lactamase stability, and preliminary susceptibility testing criteriaP C Fuchs, R N Jones, A L Barry, et al.
Diagnostic Microbiology and Infectious Disease|November 1, 1990
Interpretive criteria, quality control guidelines, and drug stability studies for susceptibility testing of cefotaxime, cefoxitin, ceftazidime, and cefuroxime against Neisseria gonorrhoeaeR N Jones, P C Fuchs, J A Washington, et al.
Pageof 82